Barriers to prescribing proprotein convertase subtilisin‐kexin type 9 inhibitors after coronary revascularisation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Barriers to prescribing proprotein convertase subtilisin‐kexin type 9 inhibitors after coronary revascularisation

Published:2022-09-04 Issue: Volume: Page:
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Nguy Jenny¹²^ORCID,Hitchen Sarah A.¹²^ORCID,Lan Nick S. R.²³⁴^ORCID,Dwivedi Girish³⁴⁵,Larbalestier Robert⁶,Yeap Bu B.²⁴^ORCID,Fegan P. Gerry²⁷^ORCID

Affiliation:

1. Department of Pharmacy Fiona Stanley Hospital Perth Western Australia Australia

2. Department of Endocrinology and Diabetes Fiona Stanley Hospital Perth Western Australia Australia

3. Department of Cardiology Fiona Stanley Hospital Perth Western Australia Australia

4. Internal Medicine, Medical School The University of Western Australia Perth Western Australia Australia

5. Medical School Harry Perkins Institute of Medical Research Perth Western Australia Australia

6. Department of Cardiothoracic Surgery Fiona Stanley Hospital Perth Western Australia Australia

7. Medical School Curtin University Perth Western Australia Australia

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.15700

Reference32 articles.

1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

2. Impact of Lipids on Cardiovascular Health

3. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

4. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

5. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insight into the Evolving Role of PCSK9;Metabolites;2022-03-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3